重大事项：
健康之路(02587)每股定价7.8港元 香港公开发售获34.42倍认购
英诺赛科(02577) 每股发售价为30.86 港元 公开发售获轻微超额认购
讯飞医疗科技(02506)公开发售获3.66倍认购 全球发售净筹约5.07亿港元
石四药集团(02005)：呋塞米注射液已取得国家药监局仿制药质量和疗效一致性评价
亚盛医药-B(06855)拟申请在纳斯达克全球精选市场(或纳斯达克)上市美国存托股份
恒投证券(01476)和华融综合投资拟以现金出资方式向新华基金注资
中国心连心化肥(01866)：广西基地一期复合肥项目成功投产
浙商银行(02016)拟向浙银金租增资不超过10.2亿元
康耐特光学(02276)：香港歌尔泰克拟收购不超4280万股公司股份
碧桂园(02007)附属拟以20亿元出售长鑫科技约1.56%的股本权益
VESYNC(02148)获要约人VICTORY III CO.,LTD透过协议安排提私有化 12月30日复牌
经营业绩：
雅迪控股(01585)预期年度纯利为约12亿-14亿元
深圳高速公路股份(00548)：11月外环项目路费收入1.01亿元 同比减少3.41%
如需了解更多详情，请参阅智通财经网(www.zhitongcaijing.com)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.